Eagle Bay Advisors’s Emergent Biosolutions EBS Stock Holding History

Eagle Bay Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-119	Closed	-$5K	–	482
2021 Q4	$5K	Buy	+119	New	+$5.38K	﹤0.01%	782

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Eagle Bay Advisors's EBS Position: Q1 2022 in Review

Eagle Bay Advisors sold out of Emergent Biosolutions (EBS) in Q1 2022, closing a stake of 119 shares — an estimated $5K sold.

Eagle Bay Advisors first reported a position in EBS in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 255 funds tracked by Wall St. Rank hold EBS as of Q1 2022.

Eagle Bay Advisors reported no remaining Emergent Biosolutions position as of Q1 2022 after selling out during the quarter.
Eagle Bay Advisors sold 119 Emergent Biosolutions shares in Q1 2022, an estimated $5K.
Eagle Bay Advisors first reported a position in Emergent Biosolutions in Q4 2021 and held it in 1 quarter.
Eagle Bay Advisors's Emergent Biosolutions position peaked at $5K in Q4 2021.
255 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.